Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10914801 | Molecular Oncology | 2015 | 12 Pages |
Abstract
Conclusions: The performance of a serum metabolomic prognostic model for disease relapse in individuals with ER-negative early stage breast cancer is promising. A confirmation study is ongoing to better define the potential of metabolomics as a host and tumour-derived prognostic tool.
Keywords
CPMGMSKCCROCCERMHER21H NMRAUCCarr–Purcell–Meiboom–GillBiomarkerRandom forestBreast cancerMass spectroscopyNuclear magnetic resonance spectroscopyMetabolomicsMetabolitesMemorial Sloan-Kettering Cancer Centerarea under the curveMicrometastasesproton nuclear magnetic resonanceGas chromatographyoestrogen receptorHuman epidermal growth factor receptor 2
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Leonardo Tenori, Catherine Oakman, Patrick G. Morris, Ewa Gralka, Natalie Turner, Silvia Cappadona, Monica Fornier, Cliff Hudis, Larry Norton, Claudio Luchinat, Angelo Di Leo,